Genexine Inc. and SCM Lifescience have jointly won the bidding to acquire US firm Argos Therapeutics Inc., which had been put up for sale by the Delaware bankruptcy court, for about KRW12.5bn ($11m), in a move that the two South Korean biotechs hope will accelerate their global R&D and market entry efforts.
The joint acquisition comes amid the Korean biotech industry’s ongoing robust efforts to enter major